Extrahepatic Manifestations of Hepatitis C Virus Infection

Clinics in Liver Disease

Volumn 12, Issue 3, 2008, Pages 611-636

  Zignego, Anna Linda ^a   Craxì, Antonio ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; PEGINTERFERON; RIBAVIRIN; RITUXIMAB;

ARTHROPATHY; AUTOIMMUNE DISEASE; BONE DISEASE; CARDIOVASCULAR DISEASE; CRYOGLOBULINEMIA; DIET THERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENDOCRINE DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; LUNG DISEASE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MUSCLE DISEASE; NEUROLOGIC DISEASE; PATHOGENESIS; PLASMAPHERESIS; PREVALENCE; REVIEW;

HEPACIVIRUS; HEPATITIS C; HUMANS; KIDNEY DISEASES; LYMPHOPROLIFERATIVE DISORDERS; MUSCULOSKELETAL DISEASES; NERVOUS SYSTEM DISEASES; SKIN DISEASES;

EID: 46949094313     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.03.012     Document Type: Review

References (201)

1. Zignego A.L., and Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 31 (1999) 369-376
2. Cacoub P., Poynard T., Ghillani P., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C. Arthritis Rheum 42 (1999) 2204-2212
3. Ferri C., Zignego A.L., and Pileri S. Cryoglobulins. In: Young N.S., Gerson S.L., and High K.A. (Eds). Clinical hematology vol (2005), Elsevier, Mosby (MO) 625-636 Chapter 24
4. Misiani R., Bellavita P., Fenili D., et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 117 (1992) 573-577
5. Ferri C., Monti M., La Civita L., et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 82 (1993) 3701-3704
6. Zignego A.L., Ferri C., Giannini C., et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol 142 (1997) 545-555
7. Agnello V., Chung R.T., and Kaplan L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. [see comments]. N Engl J Med 327 (1992) 1490-1495
8. Brouet J.C., Clauvel J.P., Danon F., et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 57 (1974) 775-788
9. Agnello V. Hepatitis C virus infection and type II cryoglobulinemia: an immunological perspective. [published erratum appears in Hepatology 1998 Mar;27(3):889]. Hepatology 26 (1997) 1375-1379
10. Lunel F., Musset L., Cacoub P., et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 106 (1994) 1291-1300
11. Wong V.S., Egner W., Elsey T., et al. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 104 (1996) 25-31
12. Pawlotsky J.M., Roudot-Thoraval F., Simmonds P., et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 122 (1995) 169-173
13. Ferri C., Sebastiani M., Giuggioli D., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33 (2004) 355-374
14. Meltzer M., and Franklin E.C. Cryoglobulinemia-a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med 40 (1966) 828-836
15. Meltzer M., Franklin E.C., Elias K., et al. Cryoglobulinemia-a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 40 (1966) 837-856
16. Haddad J., Deny P., Munz-Gotheil C., et al. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 339 (1992) 321-323
17. Koike K., Moriya K., Ishibashi K., et al. Sialadenitis histologically resembling Sjogren's syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci U S A 94 (1997) 233-236
18. De Vita S., Sacco C., Sansonno D., et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood 90 (1997) 776-782
19. Scott C.A., Avellini C., Desinan L., et al. Chronic lymphocytic sialoadenitis in HCV-related chronic liver disease: comparison of Sjogren's syndrome. Histopathology 30 (1997) 41-48
20. Ferri C., Longombardo G., La Civita L., et al. Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease. J Intern Med 236 (1994) 31-36
21. Daghestani L., and Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med 106 (1999) 347-354
22. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 54 (1998) 650-671
23. Tarantino A., Campise M., Banfi G., et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 47 (1995) 618-623
24. Johnson R.J., Gretch D.R., Yamabe H., et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. [see comments]. N Engl J Med 328 (1993) 465-470
25. Beddhu S., Bastacky S., and Johnson J.P. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 81 (2002) 398-409
26. Ferri C., Marzo E., Longombardo G., et al. Interferon-alfa in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81 (1993) 1132-1136
27. Bartenschlager R., Ahlborn-Laake L., Mous J., et al. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol 67 (1993) 3835-3844
28. Cacoub P., Fabiani F.L., Musset L., et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med 96 (1994) 124-132
29. Borowski P., Heiland M., Oehlmann K., et al. Nonstructural protein 3 of hepatitis C virus inhibits phosphorylation mediated by cAMP-dependent protein kinase. Eur J Biochem 237 (1996) 611-618
30. Kayali Z., Buckwold V.E., Zimmerman B., et al. Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis. Hepatology 36 (2002) 978-985
31. Saadoun D., Asselah T., Resche-Rigon M., et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatology 43 (2006) 1337-1345
32. Ferri C., Zignego A.L., and Pileri S.A. Cryoglobulins. J Clin Pathol 55 (2002) 4-13
33. Zignego A.L., Giannini C., and Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 13 (2007) 2467-2478
34. Musset L., Diemert M.C., Taibi F., et al. Characterization of cryoglobulins by immunoblotting. Clin Chem 38 (1992) 798-802
35. Sansonno D., De Vita S., Iacobelli A.R., et al. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 160 (1998) 3594-3601
36. Magalini A.R., Facchetti F., Salvi L., et al. Clonality of B-cells in portal lymphoid infiltrates of HCV-infected livers. J Pathol 185 (1998) 86-90
37. Racanelli V., Sansonno D., Piccoli C., et al. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 167 (2001) 21-29
38. Vallat L., Benhamou Y., Gutierrez M., et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 50 (2004) 3668-3678
39. Monteverde A., and Pileri S. Lymphoproliferative diseases of uncertain classification. Ann Ital Med Int 6 (1991) 162-170
40. Ferri C., Pileri S., and Zignego A.L. Hepatitis C virus infection and non-Hodgkin's lymphoma. In: Geodert J.J. (Ed). Infectious causes of cancer. Targets for intervention (2000), The Human Press inc., Totowa (NJ) 349-368
41. Ferri C., Zignego A.L., and Pileri S.A. Cryoglobulinemia (2006), Elsevier, Philadelphia
42. Santini G.F., Crovatto M., Modolo M.L., et al. Waldenstrom macroglobulinemia: a role of HCV infection?. Blood 82 (1993) 2932
43. Pozzato G., Mazzaro C., Crovatto M., et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 84 (1994) 3047-3053
44. Mussini C., Ghini M., Mascia M.T., et al. Monoclonal gammopathies and hepatitis C virus infection. Blood 85 (1995) 1144-1145
45. Mangia A., Clemente R., Musto P., et al. Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia 10 (1996) 1209-1213
46. Mazzaro C., Zagonel V., Monfardini S., et al. Hepatitis C virus and non-Hodgkin's lymphomas. [see comments]. Br J Haematol 94 (1996) 544-550
47. Musto P., Dell'Olio M., Carotenuto M., et al. Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists?. Blood 88 (1996) 752-754
48. Silvestri F., Barillari G., Fanin R., et al. Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma. Ann Oncol 9 (1998) 499-504
49. Ferri C., Monti M., La Civita L., et al. Hepatitis C virus infection in non-Hodgkin's B-cell lymphoma complicating mixed cryoglobulinaemia. Eur J Clin Invest 24 (1994) 781-784
50. Monti G., Pioltelli P., Saccardo F., et al. Incidence and characteristics of non-Hodgkin's lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 165 (2005) 101-105
51. Ferri C., Caracciolo F., La Civita L., et al. Hepatitis C virus infection and B-cell lymphomas. [letter]. Eur J Cancer 10 (1994) 1591-1592
52. Ferri C., La Civita L., Caracciolo F., et al. Non-Hodgkin's lymphoma: possible role of hepatitis C virus. [letter]. JAMA 272 (1994) 355-356
53. Luppi M., Grazia Ferrari M., Bonaccorsi G., et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 10 (1996) 351-355
54. Pioltelli P., Zehender G., Monti G., et al. HCV and non-Hodgkin's lymphoma. Lancet 347 (1996) 624-625
55. Silvestri F., Pipan C., Barillari G., et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 87 (1996) 4296-4301
56. Brind A.M., Watson J.P., Burt A., et al. Non-Hodgkin's lymphoma and hepatitis C virus infection. Leuk Lymphoma 21 (1996) 127-130
57. Hanley J., Jarvis L., Simmonds P., et al. HCV and non-Hodgkin's lymphoma. Lancet 347 (1996) 1339
58. McColl M.D., Singer I.O., Tait R.C., et al. The role of hepatitis C virus in the aetiology of non-Hodgkin's lymphoma-a regional association?. Leuk Lymphoma 26 (1997) 127-130
59. Ellenrieder V., Weidenbach H., Frickhofen N., et al. HCV and HGV in B-cell non-Hodgkin's lymphoma. J Hepatol 28 (1998) 34-39
60. Collier J.D., Zanke B., Moore M., et al. No association between hepatitis C and B-cell lymphoma. [see comments]. Hepatology 29 (1999) 1259-1261
61. Hausfater P., Cacoub P., Rosenthal E., et al. Hepatitis C virus infection and lymphoproliferative diseases in France: a national study. The Germivic group. Am J Hematol 64 (2000) 107-111
62. Matsuo K., Kusano A., Sugumar A., et al. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95 (2004) 745-752
63. Silvestri F., and Baccarani M. Hepatitis C virus-related lymphomas. Br J Haematol 99 (1997) 475-480
64. Ascoli V., Lo Coco F., Artini M., et al. Extranodal lymphomas associated with hepatitis C virus infection. Am J Clin Pathol 109 (1998) 600-609
65. Luppi M., Longo G., Ferrari M.G., et al. Clinico-pathological characterization of hepatitis C virus-related B- cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. [see comments]. Ann Oncol 9 (1998) 495-498
66. Trepo C., Berthillon P., and Vitvitski L. HCV and lymphoproliferative diseases. Ann Oncol 9 (1998) 469-470
67. Talamini R., Montella M., Crovatto M., et al. Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 110 (2004) 380-385
68. Harris N.L., Jaffe E.S., Stein H., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. [see comments]. Blood 84 (1994) 1361-1392
69. Jaffe Es H.N., Stein H., and Vardiman J.W. Tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours (2001), IARC Press, Lyon (France)
70. Nieters A., Kallinowski B., Brennan P., et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study Epilymph. Gastroenterology 131 (2006) 1879-1886
71. De Vita S., Sansonno D., Dolcetti R., et al. Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood 86 (1995) 1887-1892
72. Luppi M., Longo G., Ferrari M.G., et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol 94 (1996) 373-375
73. Hermine O., Lefrere F., Bronowicki J.P., et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347 (2002) 89-94
74. Lefrère F., Troussard X., and Hermine O. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347 (2002) 2168-2170 (author reply)
75. Saadoun D., Suarez F., Lefrere F., et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?. Blood 105 (2005) 74-76
76. Andreone P., Zignego A.L., Cursaro C., et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 129 (1998) 294-298
77. Bartl R., Frisch B., Fateh-Moghadam A., et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 87 (1987) 342-355
78. Pileri S., Poggi S., Baglioni P., et al. Histology and immunohistology of bone marrow biopsy in multiple myeloma. Eur J Haematol Suppl 51 (1989) 52-59
79. Zignego A.L., Ferri C., Monti M., et al. Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin Exp Rheumatol 13 Suppl 13 (1995) S33-S37
80. Zignego A.L., Macchia D., Monti M., et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. [see comments]. J Hepatol 15 (1992) 382-386
81. Zignego A.L., De Carli M., Monti M., et al. Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol 47 (1995) 58-64
82. Shimizu Y.K., Igarashi H., Kanematu T., et al. Sequence analysis of the hepatitis C virus genome recovered from serum, liver, and peripheral blood mononuclear cells of infected chimpanzees. J Virol 71 (1997) 5769-5773
83. Bronowicki J.P., Loriot M.A., Thiers V., et al. Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. [see comments]. Hepatology 28 (1998) 211-218
84. Lerat H., Rumin S., Habersetzer F., et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 91 (1998) 3841-3849
85. Roque-Afonso A.M., Jiang J., Penin F., et al. Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. J Virol 73 (1999) 9213-9221
86. Sansonno D., Lotesoriere C., Cornacchiulo V., et al. Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood 92 (1998) 3328-3337
87. Roque-Afonso A.M., Ducoulombier D., Di Liberto G., et al. Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. J Virol 79 (2005) 6349-6357
88. Galli M., Zehender G., Monti G., et al. Hepatitis C virus RNA in the bone marrow of patients with mixed cryoglobulinemia and in subjects with noncryoglobulinemic chronic hepatitis type C. J Infect Dis 171 (1995) 672-675
89. Sansonno D., Lauletta G., Montrone M., et al. Virological analysis and phenotypic characterization of peripheral blood lymphocytes of hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol 143 (2006) 288-296
90. Pal S., Sullivan D.G., Kim S., et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 130 (2006) 1107-1116
91. Ivanovski M., Silvestri F., Pozzato G., et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 91 (1998) 2433-2442
92. De Re V., De Vita S., Marzotto A., et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin's lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 96 (2000) 3578-3584
93. Sansonno D., Lauletta G., De Re V., et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 34 (2004) 126-136
94. Mariette X. Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis 60 (2001) 1007-1010
95. Pileri P., Uematsu Y., Campagnoli S., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
96. Machida K., Cheng K.T., Sung V.M., et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A 101 (2004) 4262-4267
97. Zignego A.L., Giannelli F., Marrocchi M.E., et al. Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. Clin Exp Rheumatol. 15 (1997) 711-712
98. Zignego A.L., Giannelli F., Marrocchi M.E., et al. T (14;18) translocation in chronic hepatitis C virus infection. Hepatology 31 (2000) 474-479
99. Zignego A.L., Ferri C., Giannelli F., et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 137 (2002) 571-580
100. Kitay-Cohen Y., Amiel A., Hilzenrat N., et al. Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood 96 (2000) 2910-2912
101. Zuckerman E., Zuckerman T., Sahar D., et al. bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 112 (2001) 364-369
102. Sasso E.H., Martinez M., Yarfitz S.L., et al. Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t (14;18). J Immunol 173 (2004) 3549-3556
103. Libra M., Gloghini A., Navolanic P.M., et al. JH6 gene usage among HCV-associated MALT lymphomas harboring t (14;18) translocation. J Immunol 174 (2005) 3839 author reply 3839
104. Giannelli F., Moscarella S., Giannini C., et al. Effect of antiviral treatment in patients with chronic HCV infection and t (14;18) translocation. Blood 102 (2003) 1196-1201
105. Giannini C., Giannelli F., and Linda Zignego A. Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology 43 (2006) 1166-1167
106. Giannini C., Petrarca A., Monti M., et al. Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood 111 (2008) 2943-2945
107. Ferri C., Zignego A.L., Longombardo G., et al. Effect of alpha interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients. Infection 21 (1993) 93-97
108. Marcellin P., Descamps V., Martinot-Peignoux M., et al. Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology 104 (1993) 272-277
109. Misiani R., Bellavita P., Fenili D., et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. [see comments]. N Engl J Med 330 (1994) 751-756
110. Dammacco F., Sansonno D., Han J.H., et al. Natural interferon-alfa versus its combination with 6-methyl- prednisolone in the therapy of type II mixed cryoglobulinemia: a long- term, randomized, controlled study. Blood 84 (1994) 3336-3343
111. Johnson R.J., Gretch D.R., Couser W.G., et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 46 (1994) 1700-1704
112. Mazzaro C., Pozzato G., Moretti M., et al. Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia. [published erratum appears in Haematologica 1994 Sep-Oct;79(5):486]. Haematologica 79 (1994) 342-349
113. Casaril M., Capra F., Gabrielli G.B., et al. Cryoglobulinemia in hepatitis C virus chronic active hepatitis: effects of interferon-alfa therapy. J Interferon Cytokine Res 16 (1996) 585-588
114. Cohen P., Nguyen Q.T., Deny P., et al. Treatment of mixed cryoglobulinemia with recombinant interferon-alfa and adjuvant therapies. A prospective study on 20 patients. Ann Med Interne (Paris) 147 (1996) 81-86
115. Akriviadis E.A., Xanthakis I., Navrozidou C., et al. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alfa. J Clin Gastroenterol 25 (1997) 612-618
116. Casato M., Agnello V., Pucillo L.P., et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 90 (1997) 3865-3873
117. Calleja J.L., Albillos A., Moreno-Otero R., et al. Sustained response to interferon-alfa or to interferon-alfa plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 13 (1999) 1179-1186
118. Zuckerman E., Keren D., Slobodin G., et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alfa. J Rheumatol 27 (2000) 2172-2178
119. Cacoub P., Lidove O., Maisonobe T., et al. Interferon-alfa and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 46 (2002) 3317-3326
120. Mazzaro C., Zorat F., Comar C., et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 30 (2003) 1775-1781
121. Alric L., Plaisier E., Thebault S., et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 43 (2004) 617-623
122. Cacoub P., Saadoun D., Limal N., et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52 (2005) 911-915
123. Mazzaro C., Zorat F., Caizzi M., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42 (2005) 632-638
124. Levine J.W., Gota C., Fessler B.J., et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 32 (2005) 1164-1167
125. Zuckerman E., Zuckerman T., Sahar D., et al. The effect of antiviral therapy on t (14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97 (2001) 1555-1559
126. Ferri C., Giuggioli, Cazzato M., et al. HCV-related cryoglobulinemic vasculitis: update of etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 21 (2003) 578-584
127. Ballare M., Bobbio F., Poggi S., et al. A pilot study on the effectiveness of cyclosporine in type II mixed cryoglobulinemia. Clin Exp Rheumatol 13 Suppl 13 (1995) S201-S203
128. Zaja F., De Vita S., Mazzaro C., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101 (2003) 3827-3834
129. Sansonno D., De Re V., Lauletta G., et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 101 (2003) 3818-3826
130. Zaja F., Russo D., Fuga G., et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 84 (1999) 1157-1158
131. Zaja F., De Vita S., Russo D., et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 46 (2002) 2252-2254 author reply 2254-55
132. Kelaidi C., Rollot F., Park S., et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia 18 (2004) 1711-1716
133. Gisbert J.P., Garcia-Buey L., Pajares J.M., et al. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 21 (2005) 653-662
134. Hainsworth J.D., Litchy S., Burris III H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 4261-4267
135. Somer B.G., Tsai D.E., Downs L., et al. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 49 (2003) 394-398
136. Ramos-Casals M., Lopez-Guillermo A., Brito-Zeron P., et al. Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis C virus infection. Lupus 13 (2004) 969-971
137. Ferri C., La Civita L., Longombardo G., et al. Mixed cryoglobulinaemia: a crossroad between autoimmune and lymphoproliferative disorders. Lupus 7 (1998) 275-279
138. Ferri C., and Zignego A.L. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol 12 (2000) 53-60
139. Silberbogen A.K., Janke E.A., and Hebenstreit C. A closer look at pain and hepatitis C: preliminary data from a veteran population. J Rehabil Res Dev 44 (2007) 231-244
140. Piperno A., D'Alba R., Roffi L., et al. Hepatitis C virus infection in patients with idiopathic hemochromatosis (IH) and porphyria cutanea tarda (PCT). Arch Virol Suppl 4 (1992) 215-216
141. Fargion S., Piperno A., Cappellini M.D., et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 16 (1992) 1322-1326
142. Ferri C., Baicchi U., la Civita L., et al. Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda. Eur J Clin Invest 23 (1993) 851-855
143. Navas S., Bosch O., Castillo I., et al. Porphyria cutanea tarda and hepatitis C and B viruses infection: a retrospective study. Hepatology 21 (1995) 279-284
144. Nagao Y., Sata M., Tanikawa K., et al. Lichen planus and hepatitis C virus in the northern Kyushu region of Japan. Eur J Clin Invest 25 (1995) 910-914
145. Carrozzo M., Gandolfo S., Carbone M., et al. Hepatitis C virus infection in Italian patients with oral lichen planus: a prospective case-control study. J Oral Pathol Med 25 (1996) 527-533
146. Bagan J.V., Ramon C., Gonzalez L., et al. Preliminary investigation of the association of oral lichen planus and hepatitis C. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85 (1998) 532-536
147. Mignogna M.D., Lo Muzio L., Favia G., et al. Oral lichen planus and HCV infection: a clinical evaluation of 263 cases. Int J Dermatol 37 (1998) 575-578
148. del Olmo J.A., Pascual I., Bagan J.V., et al. Prevalence of hepatitis C virus in patients with lichen planus of the oral cavity and chronic liver disease. Eur J Oral Sci 108 (2000) 378-382
149. Cribier B., Garnier C., Laustriat D., et al. Lichen planus and hepatitis C virus infection: an epidemiologic study. J Am Acad Dermatol 31 (1994) 1070-1072
150. Grote M., Reichart P.A., Berg T., et al. Hepatitis C virus (HCV) infection and oral lichen planus. J Hepatol 29 (1998) 1034-1035
151. Ingafou M., Porter S.R., Scully C., et al. No evidence of HCV infection or liver disease in British patients with oral lichen planus. Int J Oral Maxillofac Surg 27 (1998) 65-66
152. van der Meij E.H., and van der Waal I. Hepatitis C virus infection and oral lichen planus: a report from The Netherlands. J Oral Pathol Med 29 (2000) 255-258
153. Nagao Y., Kameyama T., and Sata M. Hepatitis C virus RNA detection in oral lichen planus tissue. Am J Gastroenterol 93 (1998) 850
154. Arrieta J.J., Rodriguez-Inigo E., Casqueiro M., et al. Detection of hepatitis C virus replication by In situ hybridization in epithelial cells of antihepatitis C virus-positive patients with and without oral lichen planus. Hepatology 32 (2000) 97-103
155. Hussain I., Hepburn N.C., Jones A., et al. The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland. Clin Exp Dermatol 21 (1996) 283-285
156. O'Reilly F.M., Darby C., Fogarty J., et al. Porphyrin metabolism in hepatitis C infection. Photodermatol Photoimmunol Photomed 12 (1996) 31-33
157. Tembl J.I., Ferrer J.M., Sevilla M.T., et al. Neurologic complications associated with hepatitis C virus infection. Neurology 53 (1999) 861-864
158. Lidove O., Cacoub P., Maisonobe T., et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. Ann Rheum Dis 60 (2001) 290-292
159. Rosner I., Rozenbaum M., Toubi E., et al. The case for hepatitis C arthritis. Semin Arthritis Rheum 33 (2004) 375-387
160. Fiore C.E., Riccobene S., Mangiafico R., et al. Report of a new case with involvement of the OPG/RANKL system. Osteoporos Int 16 (2005) 2180-2184
161. Manganelli P., Giuliani N., Fietta P., et al. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?. Clin Rheumatol 24 (2005) 296-300
162. Muzio A.D., Bonetti B., Capasso M., et al. Hepatitis C virus infection and myositis: a virus localization study. Neuromuscul Disord 13 (2002) 68-71
163. Pateron D., Hartmann D.J., Duclos-Vallee J.C., et al. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 16 (1992) 244-245
164. Huang M.J., Wu S.S., and Liaw Y.F. Thyroid abnormalities in patients with chronic viral hepatitis. Hepatology 20 (1994) 1651-1652
165. Preziati D., La Rosa L., Covini G., et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alfa-2a. Eur J Endocrinol 132 (1995) 587-593
166. Fernandez-Soto L., Gonzalez A., Escobar-Jimenez F., et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med 158 (1998) 1445-1448
167. Huang M.J., Tsai S.L., Huang B.Y., et al. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf) 50 (1999) 503-509
168. Prentice L.M., Phillips D.I., Sarsero D., et al. Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase. Acta Endocrinol (Copenh) 123 (1990) 493-498
169. Lenzi M., Johnson P.J., McFarlane I.G., et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 338 (1991) 277-280
170. McFarlane I.G. Autoimmunity and hepatotropic viruses. Semin Liver Dis 11 (1991) 223-233
171. Minelli R., Braverman L.E., Giuberti T., et al. Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alfa treatment. Clin Endocrinol (Oxf) 47 (1997) 357-361
172. Marazuela M., Garcia-Buey L., Gonzalez-Fernandez B., et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alfa therapy. Clin Endocrinol (Oxf) 44 (1996) 635-642
173. Antonelli A., Ferri C., and Fallahi P. Thyroid cancer in patients with hepatitis C infection. JAMA 281 (1999) 1588
174. Montella M., Crispo A., Pezzullo L., et al. Is hepatitis C virus infection associated with thyroid cancer? A case-control study. Int J Cancer 87 (2000) 611-612
175. Antonelli A., Ferri C., Fallahi P., et al. Thyroid cancer in HCV-related mixed cryoglobulinemia patients. Clin Exp Rheumatol 20 (2002) 693-696
176. Zignego A.L., Ferri C., Pileri S.A., et al. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 39 (2007) 2-17
177. Hsieh M.C., Yu M.L., Chuang W.L., et al. Virologic factors related to interferon-alfa induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 142 (2000) 431-437
178. Prummel M.F., and Laurberg P. Interferon-alfa and autoimmune thyroid disease. Thyroid 13 (2003) 547-551
179. Muratori L., Bogdanos D.P., Muratori P., et al. Susceptibility to thyroid disorders in hepatitis C. Clin Gastroenterol Hepatol 3 (2005) 595-603
180. Simo R., Hernandez C., Genesca J., et al. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19 (1996) 998-1000
181. Caronia S., Taylor K., Pagliaro L., et al. Further evidence for an association between noninsulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30 (1999) 1059-1063
182. Knobler H., Schihmanter R., Zifroni A., et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 75 (2000) 355-359
183. Mehta S.H., Brancati F.L., Sulkowski M.S., et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133 (2000) 592-599
184. Mason A. Viral induction of type 2 diabetes and autoimmune liver disease. J Nutr 131 (2001) 2805S-2808S
185. Ryu J.K., Lee S.B., Hong S.J., et al. Association of chronic hepatitis C virus infection and diabetes mellitus in Korean patients. Korean J Intern Med 16 (2001) 18-23
186. Antonelli A., Ferri C., Fallahi P., et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 28 (2005) 2548-2550
187. Noto H., and Raskin P. Hepatitis C infection and diabetes. J Diabetes Complications 20 (2006) 113-120
188. Mason A.L., Lau J.Y., Hoang N., et al. Association of diabetes mellitus
189. Ishizaka N., Ishizaka Y., Takahashi E., et al. Association between hepatitis C virus seropositivity, carotid artery plaque, and intima-media thickening. Lancet 359 (2002) 133-135
190. Ishizaka N., Ishizaka Y., Takahashi E., et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. Circulation 105 (2002) 1028-1030
191. Ueda T., Ohta K., Suzuki N., et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 146 (1992) 266-268
192. Ohta K., Ueda T., Nagai S., et al. Pathogenesis of idiopathic pulmonary fibrosis-is hepatitis C virus involved?. Nihon Kyobu Shikkan Gakkai Zasshi 315 (1993) 32-35
193. Ferri C., La Civita L., Fazzi P., et al. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. Br J Rheumatol 36 (1997) 360-365
194. Matsumori A., Ohashi N., Hasegawa K., et al. Hepatitis C virus infection and heart diseases: a multicenter study in Japan. Jpn Circ J 62 (1998) 389-391
195. Boddi M., Abbate R., Chellini B., et al. HCV infection facilitates asimptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis 39 (2007) 54-59
196. Dwight M.M., Kowdley K.V., Russo J.E., et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 49 (2000) 311-317
197. Forton D.M., Thomas H.C., Murphy C.A., et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35 (2002) 433-439
198. Hilsabeck R.C., Perry W., and Hassanein T.I. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35 (2002) 440-446
199. Cozzi A., Zignego A.L., Carpendo R., et al. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 13 (2006) 402-408
200. Korsmeyer S.J. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59 (1999) 1693s-1700s
201. Tighe H., Warnatz K., Brinson D., et al. Peripheral deletion of rheumatoid factor B cells after abortive activation by IgG. Proc Natl Acad Sci U S A 94 (1997) 646-651